1. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Issue 10 (October 2020) Authors: Kumar, Shaji K; Jacobus, Susanna J; Cohen, Adam D; Weiss, Matthias; Callander, Natalie; Singh, Avina K; Parker, Terri L; Menter, Alexander; Yang, Xuezhong; Parsons, Benjamin; Kumar, Pankaj; Kapoor, Prashant; Rosenberg, Aaron; Zonder, Jeffrey A; Faber, Edward; Lonial, Sagar; Anderson, Kenneth C; R... Journal: Lancet oncology Issue: Volume 21:Issue 10(2020) Page Start: 1317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗